GlassScriptPhysician profile
Barbara Onumah
NPI 1548456379
$11,919.55
in general payments reported to CMS, 2019-2025
33 companies · $4,284 in 2025
The $4,284 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,876 · 2020: $2,663 · 2021: $110 · 2022: $235 · 2023: $608 · 2024: $1,144 · 2025: $4,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,232 · Consulting Fee: $2,790 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.55 |
| Consulting Fee | $2,790.00 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $5,200.00 | 2019-2020 | |
| Novo Nordisk INC | $3,012.03 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $950.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $441.10 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $325.54 | 2023-2025 | Korlym |
| Insulet Corporation | $213.13 | 2023-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $189.89 | 2019-2024 | |
| Dexcom, INC. | $185.33 | 2019-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $144.30 | 2023-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $124.57 | 2019-2025 | Unithroid |
| Amgen INC. | $124.46 | 2023-2025 | Tepezza, Evenity |
| Abbvie INC. | $112.51 | 2024-2025 | |
| Medtronic, INC. | $103.91 | 2024-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $95.41 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $84.08 | 2023-2025 | Yorvipath |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.51 | 2023-2025 | Jardiance, Tradjenta |
| Recordati_rare_diseases_inc. | $65.46 | 2023-2025 | Isturisa, Signifor Lar |
| Madrigal Pharmaceuticals | $62.35 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $59.39 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.76 | 2024 | |
| Abbott Laboratories | $42.95 | 2023-2024 | Freestyle Libre 3 |
| Becton, Dickinson and Company | $38.97 | 2019-2022 | |
| Antares Pharma, INC. | $30.51 | 2024 | Xyosted |
| Vivus LLC | $29.24 | 2024 | Qsymia |
| Alexion Pharmaceuticals, INC. | $27.58 | 2025 | Strensiq |
| Amphastar Pharmaceuticals, INC. | $21.69 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.40 | 2019 | |
| Beta Bionics, INC. | $17.51 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Avanir Pharmaceuticals, INC. | $16.78 | 2019 | |
| Embecta Corp. | $16.57 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascensia Diabetes Care US INC. | $13.92 | 2023 | |
| Gilead Sciences, INC. | $13.65 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Onumah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.